Previous 10 | Next 10 |
AC Immune press release (NASDAQ:ACIU): FY Non-GAAP EPS of -CHF0.99. As of December 31, 2021 the Company had a total cash balance of CHF 198.2 million, composed of CHF 82.2 million in cash and cash equivalents and CHF 116.0 million in short-term fin...
Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial...
LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key opinion leader (KOL) webinar on alpha-synuclein (a-syn) as a target in ...
ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson’s disease, Lewy Body Dementia, MSA and others AC Immune to host ...
Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD TM ) AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies LAUSANNE, Swit...
AC Immune (NASDAQ:ACIU) reported interim 10-week data from a high-dose cohort of a phase 1b/2a trial evaluating ACI-35.030, a phosphorylated-Tau (pTau) vaccine candidate in people with early Alzheimer’s disease (AD). The company said new interim data showed that the high-dose of A...
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or high-dose cohorts to date Interim data support plans f...
AC Immune (NASDAQ:ACIU) will advance an optimized version of ACI-24, currently in preclinical stage, into the clinic for Alzheimer's disease. The decision is supported by data published in the journal Brain Communications that showed an optimized ACI-24 vaccine formulation induced a broad pol...
Snap (NYSE:SNAP) +40% on Q4 results. Bill.com Holdings (NYSE:BILL) +23% on Q2 results. Sphere 3D (NASDAQ:ANY) +16% on purchase of 60K Numiner NM440 BTC Miners. Unity Software (NYSE:U) +14% on Q4 results. Standard Lithium (NYSE:SLI) +12% set to rebound from short seller's s...
Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates Data further support advancing optimized ACI-24 into the next stage of clinical development for A...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...